NCT03051217View on ClinicalTrials.gov

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

November 19, 2018

Study Completion Date

January 16, 2019

Conditions
Moderate to Severe PsoriasisGeneralized Pustular Psoriasis and Erythrodermic Psoriasis
Interventions
OTHER

Placebo

"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W"

DRUG

Certolizumab Pegol

"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"

Trial Locations (33)

Unknown

Ps0017 024, Asahikawa

Ps0017 012, Bunkyō City

Ps0017 010, Chiyoda-Ku

Ps0017 007, Chūōku

Ps0017 004, Fukuoka

Ps0017 039, Fukushima

Ps0017 028, Gifu

Ps0017 040, Hamamatsu

Ps0017 013, Itabashi-Ku

Ps0017 022, Kobe

Ps0017 032, Kumamoto

Ps0017 031, Kurume

Ps0017 021, Kyoto

Ps0017 041, Matsumoto

Ps0017 009, Minatoku

Ps0017 033, Miyazaki

Ps0017 016, Nagoya

Ps0017 029, Nankoku

Ps0017 005, Obihiro

Ps0017 017, Osaka

Ps0017 042, Osaka

Ps0017 037, Ōsaka-sayama

Ps0017 001, Sapporo

Ps0017 027, Sendai

Ps0017 015, Shimotsuke

Ps0017 008, Shinagawa-Ku

Ps0017 002, Shinjuku

Ps0017 003, Shinjuku

Ps0017 011, Shinjuku

Ps0017 014, Shinjuku

Ps0017 034, Sumida City

Ps0017 038, Takaoka

Ps0017 025, Tsu

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03051217 - A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis | Biotech Hunter | Biotech Hunter